ArticleNanomedicine (London, England)2025
Bgh/GelMA/CMCS hydrogel with bone MSC-EVs for lunate defect repair.
Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functionalized GelMA-based hydrogels for osteoimmunomodulation and bone regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Advances in enhanced mesenchymal stem cell technologies: innovations and therapeutic applications.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeKienböck disease, characterized by avascular necrosis of the lunate bone, remains difficult to treat. This study developed a 3D-printed Bgh/GelMA/CMCS (BGC) hydrogel scaffold loaded with bone mesenchymal stem cells (MSC-EVs) for lunate bone repair.
methodMSC-EVs were isolated using ultracentrifugation, and incorporated into BGC lunate-like scaffolds via 3D-printing. Scaffold properties, including surface morphology, biomechanical strength, degradation, and EV release, were investigated. Rabbit lunate defects were treated with these hydrogel scaffolds, and their structure and stability were evaluated. Inflammation, neovascularization, and bone generation were analyzed.
resultsThe BGC hydrogel scaffold loaded with MSC-EVs maintained bioactivity with excellent biocompatibility and stability, releasing EVs slowly over a month. In vitro, EVs@BGC hydrogel promoted HUVEC and BMSC proliferation, migration, and tube formation. In vivo, the M1/M2 ratio and inflammatory factors decreased significantly one-week post-implantation, while CD31 and VEGF-positive cells increased at four weeks, and BMP2 and OPN-positive cells at eight weeks. HE staining and Masson's trichrome showed better bone generation in the EVs@BGC group.
conclusionsThe EVs@BGC lunate-like hydrogel scaffold provides structural support and sustained MSC-EV release, reducing early inflammation and enhancing neovascularization and bone formation over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.